drugset / Trial / NCT05153408
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.
Timeline
- Start
- 2022-01-13
- Primary completion
- 2022-12-09
- Completion
- 2022-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BLU-701 | Unknown | — | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Osimertinib | Small molecule | — | Oral |
| Background | Pemetrexed | Small molecule | — | Intravenous |